|Systematic (IUPAC) name|
|CAS Registry Number|
|Molecular mass||230.306 g/mol|
Adverse effects of propyphenazone
Countries that have banned propyphenazone
Excerpt from WHO comments:
- “Propyphenazone, a pyrazolone derivative with anti-inflammatory, analgesic and antipyretic activity, was introduced in 1951 for the treatment of rheumatic disorders. As it is structurally related to aminophenazone it has been associated with severe blood dyscrasias. However, it cannot be transformed into potentially carcinogenic nitrosamines and has therefore been widely used as a replacement drug for aminophenazone. In certain countries, products containing propyphenazone have now been restricted in their indications, whereas in others they are still available, sometimes as over-the-counter preparations.”
- Sri Lanka
- South Korea - as reported by PharmAsia News in 2009:
- Turkey - production and sale banned in January 1986 due to incidence of severe adverse reactions.
- India- Still in use. Saridon tablets contain 150mg/tablet.
- Göres, E.; Kossowicz, J.; Schneider, H. G. (2004). "Propyphenazone. Pharmacology and use" [Propyphenazone. Pharmacology and use]. Medizinische Monatsschrift für Pharmazeuten (in German) 27 (3): 72–76.
- Akyel, A.; Alsancak, Y.; Yayla, Ç. R.; Şahinarslan, A.; Özdemir, M. (2011). "Acute inferior myocardial infarction with low atrial rhythm due to propyphenazone: Kounis syndrome". International Journal of Cardiology 148 (3): 352–353.
- Consolidated List of Products whose Consumption and/or Sale have been Banned, Withdrawn, Severely Restricted or not Approved by Governments, Twelfth Issue (pdf). New York: Department of Economic and Social Affairs of the United Nations Secretariat. 2005. p. 232.
- "Multi-Country Survey On Banned And Restricted Pharmaceuticals". Health Action International Asia Pacific. August 2008. p. 7.
- "Bayer’s Saridon-A Among 28 Painkillers Banned To Those Under 15 In Korea". PharmAsia News. 2009-03-12.